[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

112

1 HIV, the lack of, really, a truly effective therapy,
2 given the continued problem with access to therapies
3 by large groups of populations of HIV-infected
4 individuals, should we put on the table and seriously
5 consider that although the traditional scientific
6 paradigm would not tell us to go ahead, but would say,
7 "Wait," that perhaps we should consider in Dr. Healy's
8 fourth point, mainly: Is it time to look at a larger
9 trial, not with just one product, but with multiple
10 products so that we know: A) which one is better; and
11 B), in fact, would they be effective and at the same
12 time providing access to therapy for large numbers of
13 individuals who have either tried and failed therapy,
14 who may not have access to therapy, who might not want
15 to go on the traditional therapy?
16 So I just throw that up as a --
17 DR. ROGERS: Tony, that was too easy for
18 my question. That, in essence, was: Could we broaden
19 it to either several potential candidate vaccines?
20 And should we debate the precise question you just put
21 forth?
22 CO-CHAIRMAN CARPENTER: We're ready to do
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]